ALSO NOTED: Barr challenges Sanofi patents on $1.1B drug; Wockhardt to launch copycat Zoloft;

> Barr Laboratories is challenging Sanofi-Aventis patents on Eloxatin, a colon-cancer drug that Barr wants to copy; Eloxatin posted $1.1 billion in U.S. sales for the 12 months ended in October. Report

> India's Wockhardt got the FDA's nod for its copycat version of Zoloft, or sertraline; the generics maker plans to launch the drug within the next few weeks. Report

> The FDA plans to meet later this month to consider Entereg, a potential constipation drug co-developed by GlaxoSmithKline and Adolor. Report

> Chinese pharma's production value has grown by 20 percent annually over the past decade, according to a new report, which also points out weaknesses in the industry there. Report

> Shares of Isis Pharmaceuticals rocketed up 45 percent after the biotech announced that Genzyme had signed on as a partner to develop the promising cardiovascular drug mipomersen, its flagship product. Report

> Sirtris grabbed some headlines at the JP Morgan gathering in San Francisco with its presentation of positive, early-stage data for its closely watched therapy based on resveratrol, an ingredient in red wine that has been linked to increased longevity. Report

> WuXi's buyout deal has raised questions about scientists' pay scale. Report

And Finally... Forego those french fries and pick up a peach! A new study shows healthy habits could add up to 14 years to your life. Report

Suggested Articles

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

Krystal Biotech has started on a new manufacturing facility for eventual commercial supply of gene therapies in its pipeline.

Chinese authorities have recommended trying AbbVie's HIV combo therapy Kaletra to treat the new coronavirus ravaging the country—and spreading fast.